Migraine Pipeline Drugs Market Assessment– Forecast to 2022

Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022

• Global Migraine Pipeline Drugs Assessment – Review, Potential, Clinical Trials • Global Migraine Drugs Share By Type – Acute and Prophylaxis • Company Analysis

(c) AZOTH Analytics

January 2018

Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022  Global Coverage

 Migraine Pipeline Drugs Assessment

 Scope of the Study  Country Coverage

 Global Migraine Drugs Market – By Type (Acute and Prophylaxis)

Global Coverage

 Global Migraine Pipeline Drugs Assessment  Global Migraine Drugs Market

Country Coverage

Pipeline Drugs Coverage

 United States

 Drug X-1

 United Kingdom

 Drug X-2

 Japan

 Drug X-3

 France

 Drug X-4

 Italy

 Drug X-5

 Germany

 Drug X-6  Drug X-7

(2012-2016), By Value

Company Coverage         

Amgen Allergan Eli Lilly Alder Pharmaceuticals Teva Pharmaceuticals Vernalis Pfizer Impax Laboratories Glaxo Smithkline

 Global Migraine Drugs Market (2017-2022), By Value  Breakdown-By Type - Acute and Prophylaxis)  Global Migraine Drugs Market (2012-16), By Value  Global Migraine Drugs Market

 Migraine Drugs Market, By Value (2012-2016)  Migraine Drugs Market, By Value (2017-2022)

 Migraine Drugs Market Forecast By Value (2018-2022)

 Product Benchmarking  Policy and Regulatory Landscape  Financial Analysis  Sales  EBITDA  Business Strategy

(2017-22), By Value

(c) AZOTH Analytics

2

Table of Content S.No

Particulars

Page No.

1.

Research Methodology

16

2.

Executive Summary

17

3.

Migraine - An Overview

18

4.

3.1

Symptoms of migraine

18

3.2

Stages of Migraine

19

3.3

Types of Migraine

20

3.4

Types of migraine on the basis of frequency of occurrence

24

Treatment of Migraine

25

4.1

Goal of Migraine Treatment

26

4.2

Treatment of Migraine – Pharmacological and Non-Pharmacological

26

4.2.1

Pharmacological treatment of migraine

27

4.2.2

Pharmacological - Abortive

28

4.2.3

Pharmacological - Preventive

30

(c) AZOTH Analytics

3

Table of Content S.No

5.

Particulars

Page No.

4.2.4

Non-Pharmacological Treatment of Migraine

33

4.2.5

Non- Pharmacological - Surgical

34

4.2.6

Non- Pharmacological – Non-Surgical

35

Anti Migraine Pipeline Drugs

38

5.1

Anti-Migraine Pipeline Drugs (According to Mechanism of Working)

39

5.2

Anti Migraine Pipeline Drugs (Ergotamine) – Drug X-1

40

5.2.1

Description

41

5.2.2

Regulatory Milestones

42

5.2.3

Advantages & Disadvantages

43

5.2.4

Product Profile & Expected Launch

44

5.2.5

Clinical Trials and Status

45

5.2.6

Pivotal Clinical Trials and Results

46

5.2.7

Drug X-1 – Global Market Potential

48

5.2.8

Drug X-1 - 7Ps Analysis

50

(c) AZOTH Analytics

4

Table of Content S.No

Particulars 5.3

Anti Migraine Pipeline Drugs (Anti-5HT Receptor Agonist) – Drug X-2

Page No. 51

5.3.1

Description

52

5.3.2

Regulatory Milestones

53

5.3.3

Advantages & Disadvantages

54

5.3.4

Product Profile & Expected Launch

55

5.3.5

Clinical Trials and Status

56

5.3.6

Pivotal Clinical Trials and Results

58

5.3.7

Drug X-2 – Global Market Potential

60

5.3.8

Drug X-2 – 7Ps Analysis

62

5.4

Anti Migraine Pipeline Drugs (Anti CGRPs)

63

5.5

Anti Migraine Pipeline Drugs (Anti CGRPs) – By Drug

66

5.6

Anti Migraine Pipeline Drugs (CGRP Antagonist) - Drug X-3

67

5.6.1

Description

68

5.6.2

Regulatory Milestones

69

5.6.3

Advantages & Disadvantages

70

(c) AZOTH Analytics

5

Table of Content S.No

Particulars

5.7

Page No.

5.6.4

Product Profile & Expected Launch

71

5.6.5

Clinical Trials and Status

72

5.6.6

Pivotal Clinical Trials and Results

73

5.6.7

Drug X-3 – Global Market Potential

75

5.6.8

Drug X-3 – 7Ps Analysis

77

Anti Migraine Pipeline Drugs (Anti-CGRP Mab) - Drug X-4

80

5.7.1

Description

81

5.7.2

Regulatory Milestones

82

5.7.3

Advantages & Disadvantages

83

5.7.4

Product Profile & Expected Launch

84

5.7.5

Clinical Trials and Status

85

5.7.6

Pivotal Clinical Trials and Results

86

5.7.7

Drug X-4 – Global Market Potential

90

5.7.8

Drug X-4 – 7Ps Analysis

92

(c) AZOTH Analytics

6

Table of Content S.No

Particulars 5.8

5.9

Anti Migraine Pipeline Drugs (Anti-CGRP Mab) - Drug X-5

Page No. 93

5.8.1

Description

94

5.8.2

Regulatory Milestones

95

5.8.3

Advantages & Disadvantages

96

5.8.4

Product Profile & Expected Launch

97

5.8.5

Clinical Trials and Status

98

5.8.6

Pivotal Clinical Trials and Results

100

5.8.7

Drug X-5 – Global Market Potential

103

5.8.8

Drug X-5 – 7Ps Analysis

105

Anti Migraine Pipeline Drugs (Anti-CGRP Mab) - Drug X-6

106

5.9.1

Description

107

5.9.2

Regulatory Milestones

108

5.9.3

Advantages & Disadvantages

109

5.9.4

Product Profile & Expected Launch

110

(c) AZOTH Analytics

7

Table of Content S.No

Particulars

5.10

Page No.

5.9.5

Clinical Trials and Status

111

5.9.6

Pivotal Clinical Trials and Results

113

5.9.7

Drug X-6 – Global Market Potential

115

5.9.8

Drug X-6 – 7Ps Analysis

117

Anti Migraine Pipeline Drugs (Anti-CGRP Mab) - Drug X-7

118

5.10.1

Description

119

5.10.2

Regulatory Milestones

120

5.10.3

Advantages & Disadvantages

121

5.10.4

Product Profile & Expected Launch

122

5.10.5

Clinical Trials and Status

123

5.10.6

Pivotal Clinical Trials and Results

125

5.10.7

Drug X-7 – Global Market Potential

127

5.10.8

Drug X-7 – 7Ps Analysis

129

(c) AZOTH Analytics

8

Table of Content S.No

6.

7.

Particulars

Global Migraine Drugs Market: Growth and Forecast

Page No.

130

6.1

By Value (2012-2016)

131

6.2

By Value (2017-2022)

132

Global Migraine Drugs Market-By Type 7.1

7.2

7.3

135

Global Migraine Drugs Market, By Type : Breakdown (%)

135

7.1.1

Global Migraine Drugs Market- By Type: 2016 (%)

136

7.1.2

Global Migraine Drugs Market – By Type: 2022 (%)

137

Global Migraine Drugs Market- By Acute

139

7.2.1

By Value (2012-2016)

139

7.2.2

By Value (2017-2022)

139

Global Migraine Drugs Market- By Prophylaxis

140

7.3.1

By Value (2012-2016)

140

7.3.2

By Value (2017-2022)

140

(c) AZOTH Analytics

9

Table of Content S.No

8.

9.

10.

Particulars

Global Migraine Drugs Market: Country Analysis (U.S, U.K, Japan, France, Italy, Germany, ROW)

Page No.

141

8.1

U.S. Migraine Drugs Market, By Value (2012-2022)

142

8.2

U.K. Migraine Drugs Market, By Value (2012-2022)

144

8.3

Japan Migraine Drugs Market, By Value (2012-2022)

146

8.4

France Migraine Drugs Market, By Value (2012-2022)

148

8.5

Italy Migraine Drugs Market, By Value (2012-2022)

150

8.6

Germany Migraine Drugs Market, By Value (2012-2022)

152

8.7

ROW Migraine Drugs Market, By Value (2012-2022)

154

Market Dynamics

155

9.1

Migraine Drug Market Drivers

156

9.2

Migraine Drug Market Challenges

160

Company Profile

162

10.1.

163

Amgen

(c) AZOTH Analytics

10

Table of Content S.No

11.

Particulars

Page No.

10.2.

Allergan

164

10.3.

Eli Lilly

165

10.4.

Alder Pharmaceuticals

167

10.5.

Teva Pharmaceuticals

168

10.6.

Vernalis

169

10.7.

Pfizer

170

10.8.

Impax Laboratories

171

10.9.

Glaxo Smithkline

172

About Us

173

(c) AZOTH Analytics

11

List of Figures Figure No.

Figure Title

Page No.

Figure 1:

2 hour pain relief & pain free rates in patients treated with LEVADEX (MAP0004) compared to placebo (1 st pivotal trial)

47

Figure 2:

Improvement at two hours in people who took LEVADEX compared to Placebo (2 nd pivotal trial)

47

Figure 3:

Global Drug X-1 Market Size, By Value, Forecast, 2019-2022 (USD Billion)

48

Figure 4:

Percentage of patients achieving primary end point

59

Figure 5:

Percentage of patients achieving secondary endpoint

59

Figure 6:

Global Drug X-2 Market Size, By Value, Forecast, 2019-2022 (USD Million)

60

Figure 7:

Efficacy in 2 hour pain freedom

74

Figure 8:

Global Drug X-3 Market Size, By Value, Forecast, 2019-2022 (USD Billion)

75

Figure 9:

Reduction in Monthly migraine days – weeks 1 through 12

87

Figure 10:

Percentage of patients with ≥75% reduction in number of migraine days – weeks 1 through 24

88

Figure 11:

Percentage of patients with 100% response rate (no migraine in any given month) – months 1 through 6

89

Figure 12:

Global Drug X-4 Market Size, By Value, Forecast, 2019-2022 (USD Million)

90

Figure 13:

Global Drug X-5 Market Size, By Value, Forecast, 2019-2022 (USD Million)

103

Figure 14:

Global Drug X-6 Market Size, By Value, Forecast, 2019-2022 (USD Million)

115

Figure 15:

Monthly migraine days reduction vs placebo in previous prophylactic drugs failure group

125

Figure 16:

Reduction in days using acute pain medications in recent drug overuse group

125

Figure 17:

Global Drug X-7 Market Size, By Value, Forecast, 2019-2022 (USD Million)

127

Figure 18:

Global Migraine Drugs Market Size, By value, 2012-2016 (USD Billion)

131

Figure 19:

Global Migraine Drugs Market Size, By Value, Forecast, 2017-2022 (USD Billion)

132

(c) AZOTH Analytics

12

List of Figures Figure No.

Figure Title

Page No.

Figure 20:

Global consumption of chocolate confectionary, By volume (in 1000 metric tones)

134

Figure 21:

Global Migraine Drugs Market Share, By Type, 2016 (%)

136

Figure 22:

Global Migraine Drugs Market Share, By Type, 2022 (%)

137

Figure 23:

Global Migraine Drugs Market, By Acute, By Value, 2012-2016 (USD Million)

139

Figure 24:

Global Migraine Drugs Market, By Acute, By Value, 2017-2022 (USD Million)

139

Figure 25:

Global Migraine Drugs Market, By Prophylaxis, By Value, 2012-2016 (USD Million)

140

Figure 26:

Global Migraine Drugs Market, By Prophylaxis, By Value, 2017-2022 (USD Million)

140

Figure 27:

U.S. Migraine Drugs Market, By Value, 2012-2016 (USD Billion)

142

Figure 28:

U.S. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)

142

Figure 29:

U.S Adult Migraine Patients, In Percentage

143

Figure 30:

U.S Migraine Patients, By gender, In Percentage

143

Figure 31:

U.K Migraine Drugs Market, By Value, 2012-2016 (USD Billion)

144

Figure 32:

U.K. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)

144

Figure 33:

U.K. Migraine Patient, In Percentage

145

Figure 34:

NHS Budget for mental illness, In Billion

145

Figure 35:

Japan Migraine Drugs Market, By Value, 2012-2016 (USD Billion)

146

Figure 36:

Japan Migraine Drugs Market, By Value, 2017-2022 (USD Billion)

146

Figure 37:

Japan Migraine Patient out of total population, In Percentages

147

Figure 38:

France Migraine Drugs Market, By Value, 2012-2016 (USD Billion)

148

Figure 39:

France Migraine Drugs Market, By Value, 2017-2022 (USD Billion)

148

(c) AZOTH Analytics

13

List of Figures Figure No.

Figure Title

Page No.

Figure 40:

France Migraine Patient, In Percentage

149

Figure 41:

Unemployment rate in France in percentage

149

Figure 42:

Italy Migraine Drugs Market, By Value, 2012-2016 (USD Billion)

150

Figure 43:

Italy Migraine Drugs Market, By Value, 2017-2022 (USD Billion)

150

Figure 44:

Italy Migraine Patient out of total population, In Percentages

151

Figure 45:

Italy Unemployment rate, In Percentages

151

Figure 46:

Germany Migraine Drugs Market, By Value, 2012-2016 (USD Billion)

152

Figure 47:

Germany Migraine Drugs Market, By Value, 2017-2022 (USD Billion)

152

Figure 48:

Germany Migraine Patient out of total population, In Percentages

153

Figure 49:

First Time asylum application, In Number

153

Figure 50:

ROW Migraine Drugs Market, By Value, 2012-2016 (USD Billion)

154

Figure 51:

ROW Migraine Drugs Market, By Value, 2017-2022 (USD Billion)

154

Figure 52:

ROW Migraine Drugs Market, By Value, 2017-2022 (USD Billion)

165

(c) AZOTH Analytics

14

Research Methodology For our study of Migraine Drugs Market, we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts across the value chain of the Migraine Drug industry.

For evaluating the market size of pipeline drugs, both primary and secondary research has been conducted to validate the launch date, anticipated price and growth in the number of patients.

Market size of the actual period (2012-2016) has been evaluated on the basis of growth trends of the industry in the last five years, and confirming the findings through primary research. Annual reports of the companies are scanned to further validate the market size and to estimate the size of migraine drugs. All the relevant data points/ statistics in the forecast period are validated through relevant and reliable primary sources.

Report Focus: Global Migraine Drugs Market - Migraine Pipeline Drugs (Drug X-1, X-2, X-3, X-4, X-5, X-6, X-7) - By Type (Acute and Prophylaxis) - By Country (U.S., U.K, Japan, France, Italy, Germany) - Company Coverage (Amgen, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline)

(c) AZOTH Analytics

16

Global Fremanezumab Market Figure 14: Global Drug X-1 Market Size, By Value, Forecast, 2019-2022 (USD Million)

CAGR 2019-2022 X%

2019

2020

2021

2022

Source: Azoth Analytics Estimates Xx Xx

Xx Xx Xx Xx Xx Xx

(c) AZOTH Analytics

115

Drug X-1 – 7Ps Analysis Patent

Phase

Pathway

Patient

Physician

Payer

Partner

(c) AZOTH Analytics

50

Global Migraine Drugs Market: Sizing and Growth (2012-2016) Increase in Global Stress levels coupled with growing awareness regarding migraine and availability of its drugs propelled growth in migraine drugs market.

Figure 18: Global Migraine Drugs Market Size, By value, 2012-2016 (USD Billion) CAGR 2012-2016 X%

2012

2013

2014

2015

2016

Source: Azoth Analytics Estimates Xx Xx Xx Xx Xx Xx Xx Xx

(c) AZOTH Analytics

131

Global Heart Valve Devices Market, By Value U.S. Replacement Migraine Drugs Market Figure 27: U.S. Migraine Drugs Market, By Value,

Figure 28: U.S. Migraine Drugs Market, By Value,

2012-2016 (USD Billion)

2017-2022 (USD Billion) CAGR 2017-2022

CAGR 2012-2016

X%

X%

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

Source: Azoth Analytics Estimates Xx Xx

Xx Xx Xx Xx Xx Xx

(c) AZOTH Analytics

142

About Azoth Analytics Pvt Ltd.

Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy Application. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).

Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis

provided in the report are meant for customers’ internal use only and not for general publication or disclosure to third parties.

(c) AZOTH Analytics

22